GSK plc (GSK)
| Market Cap | 75.57B |
| Revenue (ttm) | 39.28B |
| Net Income (ttm) | 3.22B |
| Shares Out | 4.08B |
| EPS (ttm) | 0.78 |
| PE Ratio | 23.44 |
| Forward PE | 8.43 |
| Dividend | $1.55 (4.12%) |
| Ex-Dividend Date | Feb 21, 2025 |
| Volume | 3,718,703 |
| Open | 37.41 |
| Previous Close | 37.87 |
| Day's Range | 37.18 - 37.72 |
| 52-Week Range | 31.72 - 45.93 |
| Beta | 0.29 |
| Analysts | Hold |
| Price Target | 47.00 (+24.87%) |
| Earnings Date | Apr 30, 2025 |
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medi... [Read more]
Financial Performance
In 2024, GSK's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.
Financial numbers in GBP Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for GSK stock is "Hold." The 12-month stock price forecast is $47.0, which is an increase of 24.87% from the latest price.
News
Bernstein's Courtney Breen: Merck, Novo Nordisk, others at high risk from tariffs
Courtney Breen, Bernstein senior analyst, joins CNBC's 'Money Movers' to discuss how to draw the line between tariff risks and company financials in pharmaceuticals, which companies are most at risk, ...
Pharma tariffs the 'number one question' on investors' minds, Barclays says
Emily Field, head of European pharmaceuticals research at Barclays, weighs in on the potential impact of U.S. tariffs on the pharmaceuticals sector.
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in GSK plc Lawsuit - GSK
NEW YORK , March 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK). Shareholders who purchased shares of GSK during the class period listed...
Blujepa (gepotidacin) Approved by US FDA for Treatment of Uncomplicated Urinary Tract Infections (uUTIs) in Female Adults and Pediatric Patients 12 Years of Age and Older
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Blujepa (gepotidacin) for the treatment of female adults (≥40 kg) and...
US FDA approves GSK's urinary tract infection drug
The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new approvals the British drugmaker h...
GSK studying if best-selling shingles vaccine lowers dementia risk
GSK said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its best-selling shingles vaccine lowers the risk of dementia.
GSK says European regulator reviewing expanded use of asthma drug Nucala
GSK on Monday said that the European Medicines Agency has agreed to review a request to approve the British drugmaker's asthama drug Nucala as an additional treatment for chronic obstructive pulmonary...
Drugmakers agree to participate in second round of price negotiations
All drug manufacturers, including Novo Nordisk and Teva Pharmaceuticals , whose medicines are part of the second round of price talks have agreed to participate in the negotiation process, a federal h...
GSK plc (GSK) TD Cowen 45th Annual Health Care Conference (Transcript)
GSK plc (NYSE:GSK) TD Cowen 45th Annual Health Care Conference March 3, 2024 9:50 AM ET Company Participants Luke Miels - Chief Commercial Officer Conference Call Participants Steve Scala - TD Cowen ...
GSK's Twice-Yearly Depemokimab Reduces Nasal Polyp Size, Goes Under FDA Review
On Monday, the Food and Drug Administration (FDA) accepted for review GSK plc's GSK marketing application for depemokimab in two indications.
GSK abandons diversity targets following Trump pressure
British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale back or abandon such goals in response to the U.S. president's opposition to t...
Canada purchases 500,000 doses of GSK's vaccine for bird flu
The Public Health Agency of Canada said on Wednesday it has secured an initial supply of 500,000 doses of GSK's bird flu vaccine to protect individuals most at risk.
GSK's Strong Performance: Why I'm Upgrading To 'Strong Buy'
GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the fou...
Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors
Ken Griffin 's hedge fund Citadel has placed a £305 million ($390 million) short bet against GSK PLC GSK, marking the largest wager against the UK pharma giant in over a decade, reported the Financial...
PENMENVY, GSK's 5-in-1 Meningococcal Vaccine, Approved by US FDA to Help Protect Against MenABCWY
PHILADELPHIA--(BUSINESS WIRE)-- #Adolescents--PENMENVY, GSK's 5-in-1 meningococcal vaccine, approved by US FDA to help protect against MenABCWY.
US FDA approves GSK's combo meningococcal vaccine
The U.S. Food and Drug Administration (FDA) approved GSK's combination vaccine to protect against meningococcal infection for use in individuals aged 10 through 25 years, the company said on Saturday.
Hedge Fund Citadel takes short position in GSK, FT reports
Hedge fund Citadel has made a 305 million pound ($384.5 million) bet against drugmaker GSK , the Financial Times reported on Friday.
India's GlaxoSmithKline Pharma reports higher profit on strong demand for respiratory drugs
India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday, led by sustained demand for its respiratory drugs and antibiotic Augmentin.
Deadline Approaching: GSK plc. (GSK) Investors Who Lost Money Urged To Contact Law Offices of Howard G.
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming April 7, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who pur...
Law Offices of Frank R. Cruz Encourages GSK plc.
LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages GSK plc. (GSK) Investors To Inquire About Securities Fraud Class Action.
Law Offices of Howard G. Smith Encourages GSK plc.
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased GSK plc. (“GSK” or the “Company”) (NYSE: GSK) A...
Securities Fraud Investigation Into GSK plc. (GSK) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of GSK plc. (“GSK” or the “C...
GSK Reported Strong Earnings, So I Reiterate My Strong Buy
GSK's 2024 results are strong, with a promising shift toward specialty medicines, particularly in HIV, respiratory conditions, and cancer, driving long-term growth. Key drugs Blenrep and Depemokimab s...
GSK Tech Ecosystem Profile - Digital Transformation Strategies and Innovation Programs
The report provides insights into GSK's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives. The report provides insights into GSK...
GSK plc. (GSK) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of GSK plc. (“GSK” or the “Company”) (NYSE: GSK) investors concerning the Company's possible violati...